📰 Recommendation Statement News
Page 13 - Recommendation Statement News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recommendation Statement. Real-time updates on events, politics, business and more.
March 13, 2023
Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) Paris and Red Bank, N.J. March 13, 2023
March 13, 2023
Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes Paris and Red Bank, N.J. March 13, 2023 Sanofi and... | March 13, 2023
March 9, 2023
invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces
March 7, 2023
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender OfferCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023(NASDAQ: FSTX) ("F-star"
February 22, 2023
Investegate announcements from Ipsen Pharma, Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
February 22, 2023
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger AgreementAlbireo stockholders are
February 1, 2023
Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales,
January 23, 2023
WILMINGTON, Del.--(BUSINESS WIRE)--Jan 23, 2023--
January 20, 2023
MUMBAI (Maharashtra) [India]/ Lexington [Kentucky], Jan 20: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO ) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an u...
January 19, 2023
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun...